Orchard Therapeutics Sets $4.25M Price for Gene Therapy
- Posted by ISPE Boston
- On March 21, 2024
Orchard Therapeutics has received FDA approval for gene therapy Lenmeldy for the treatment of children with early-onset MLD, a rare and life-threatening inherited disease of the body’s metabolic system caused by a genetic mutation. The one-time, potentially life-saving treatment will carry a list price of $4.25 million, making the treatment the most-expensive ever approved according […]
Read More